Browse Studies — Arctuva

Phase 2

A Phase 2 Trial of PD-L1 t-haNK, NAI IL-15 Superagonist (Anktiva), and Cetuximab for Immunotherapy-treated Patients With Recurrent, Metastatic HNSCC (QUILT-505)

The purpose of this research study is to test the safety and efficacy of the combination of PD-L1 t-haNK (modified immune cells), NAI (a manufactured protein t…

Head and Neck CancerHead and Neck Squamous Cell CarcinomaMetastatic Head and Neck Cancer+3 more

Estimated

~$10 – $7,500

Dana-Farber Cancer InstituteNCT06239220

Phase 2

Pilot Phase II Study to Evaluate Effect of Cetuximab Given as Single Agent After Immunotherapy With PD-1 Inhibitors in Patients With Head and Neck Squamous Cell Carcinoma

This is a Phase II treatment, non-randomized, open label clinical trial to study the efficacy of the Cetuximab when administered as single agent in recurrent/ …

Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaMetastatic Head-and-neck Squamous-cell Carcinoma

Estimated

~$10 – $6,250

Wake Forest University Health SciencesNCT04375384

Phase 3

A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN)

The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurren…

Metastatic Head-and-neck Squamous-cell CarcinomaRecurrent Head and Neck Squamous Cell Carcinoma

Estimated

~$10 – $8,750

AVEO Pharmaceuticals, Inc.NCT06064877